EKF Diagnostics recently launched a STAT-Site WB dual analyte measurement system, which it plans to demonstrate at AACC.
The new handheld analyzer measures β-ketone and glucose from whole blood. EKF will also be introducing its newest hemoglobin analyzer for the U.S. market, the Hemo Control, which provides near patient hemoglobin and hematocrit results in one test as quickly as 25 seconds.
At AACC, the company also will highlight the Lucica Glycated Albumin-L, which is manufactured by Asahi Kasei Pharma. It is a specific test for glycated albumin, which is sold in the U.S. exclusively by EKF Diagnostics. The test enables intermediate term glycemic monitoring of diabetics over the preceding 2-3 weeks.
Glycated Albumin levels are not affected by the life span of red blood cells (“RBC”), and therefore it is a useful substitute when the HbA1c interpretation is problematic such as in the presence of hemoglobinopathies, iron deficiency, and anemias. Another key feature of glycated albumin is that it changes more rapidly and markedly than HbA1c. Therefore, GA is a good marker to monitor the effects of changes in therapy in patients with diabetes when more rapid treatment responses are needed.